Company intelligence / Profile preview

Exocure

Ownership: Private
Development stage: Preclinical

Overview

Exocure has developed a proprietary exosome platform with seven owned and three licensed patents. The company’s technology enables intracellular and cell-specific delivery of therapeutic molecules via exosomes. Their pipeline targets major unmet needs in oncology (cancer metastasis—melanoma/colon cancer), metabolic diseases (Type II diabetes/obesity), and inflammatory conditions such as DED and cytokine storms. They anticipate marketable products in metabolic diseases within 2–3 years and clinical trials in oncology/infection within one year.

Therapeutic areas: OncologyPulmonologyEndocrinologyImmunologyOphthalmology
Modalities: Exosome-based therapeutics (exosomes loaded with proteins and RNA)
Industry: Biotech

Beyond the preview

Go deeper on Exocure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exocure.

Explore the full profile